While not used to guide treatment, ESR and CRP typically normalize within two to four weeks after initiating therapy. 2,4 Minor increases in ESR can occur during the prednisone taper, but this does ...

Giant cell arteritis is the most common form of systemic vasculitis in people over the age of 50. It affects large‐ and medium‐sized blood vessels, particularly in the head—although not exclusively.

Exposure to environmental particulate matter ≤ 10 μm in diameter (PM 10) is associated with an increased risk for giant cell arteritis, particularly in older individuals aged ≥ 70 years and those with ...

Please provide your email address to receive an email when new articles are posted on . KIAWAH ISLAND, S.C. — Temporal artery ultrasound and EULAR score are reliable means for diagnosing giant cell ...

Coath et al. [10] formed a multidisciplinary steering committee of rheumatologists, ophthalmologists, nursing staff and representation from the patient charity Polymyalgia Rheumatica and Giant Cell ...

An observational study was conducted across three Spanish hospitals to compare two glucocorticoid regimens in treating 151 patients newly diagnosed with giant cell arteritis (mean age, 74.6 years; 71% ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of ...

Please provide your email address to receive an email when new articles are posted on . Although it is known that the selective Janus kinase (JAK) inhibitor upadacitinib (Rinvoq, AbbVie) blocks the ...

SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck. Symptoms include, head ...

More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found ...

Secukinumab (Cosentyx) showed promise as a steroid-sparing agent in giant cell arteritis, a researcher reported here. In a phase II trial that enrolled 52 patients, 70.1% (95% CI 51.6-84.9) of those ...

The final 2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis. Credit: Annals of the Rheumatic Diseases (2022). DOI: 10.1136/ard-2022-223480 Giant cell ...